NRSN

NeuroSense Therapeutics Ltd. NASDAQ Listed Dec 9, 2021

Healthcare ·Biotechnology ·IL · neurosense-tx.com

$0.88

Mkt Cap $21.6M

52w Low $0.63 12.5% of range 52w High $2.60

50d MA $0.79 200d MA $1.03

P/E (TTM) -2.0x

EV/EBITDA -1.8x

P/B —

Debt/Equity -0.1x

ROE 713.1%

P/FCF -2.6x

RSI (14) —

ATR (14) —

Beta 1.68

50d MA $0.79

200d MA $1.03

Avg Volume 158.0K

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

SIC Code

2834

CIK (SEC)

1875091

Phone

972 9 799 6183

Building B · Herzliya, L3 4672562 · IL

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 6, 2026	AMC	-0.07	-0.22	-210.7%	0.76	+0.5%	-0.3%	-5.1%	+1.2%	-4.1%	+1.5%	—
Dec 17, 2025	AMC	—	-0.11	—	0.83	+1.2%	-1.4%	-1.0%	+3.8%	-0.1%	-2.7%	—
May 28, 2025	AMC	-0.10	-0.11	-4.8%	1.58	+1.3%	-5.1%	+2.7%	+9.7%	+3.0%	-2.3%	—
Apr 7, 2025	AMC	-0.11	-0.06	+45.5%	0.97	+2.1%	-2.3%	+0.2%	+4.1%	+7.2%	+1.9%	—
Dec 18, 2024	AMC	-0.16	-0.11	+31.2%	1.14	-0.9%	+12.3%	+6.2%	-8.1%	+2.4%	-0.8%	—
Sep 30, 2024	AMC	-0.20	-0.02	+90.0%	1.27	-3.1%	-3.9%	-0.8%	+0.8%	+3.3%	-0.8%	—
Apr 5, 2024	AMC	-0.20	-0.16	+20.0%	1.70	+2.9%	+2.4%	-1.1%	-3.5%	+1.2%	-4.8%	—
Mar 22, 2024	AMC	-0.20	-0.16	+20.0%	1.76	+0.0%	+3.4%	-6.6%	+1.8%	+5.2%	+0.5%	—
Nov 28, 2023	AMC	-0.24	0.10	+141.7%	0.89	+1.7%	+15.2%	+26.5%	+0.0%	+15.5%	-24.2%	—
Aug 16, 2023	AMC	-0.28	-0.44	-57.1%	0.91	+0.0%	-3.3%	-1.1%	+3.4%	+1.1%	+2.7%	—
Jun 1, 2023	AMC	-0.29	-0.33	-13.8%	1.57	+1.3%	+19.7%	+12.2%	-5.2%	-2.5%	-2.1%	—
Mar 22, 2023	AMC	-0.28	-0.27	+3.6%	1.65	+0.0%	+0.6%	+4.8%	-4.6%	+2.4%	+1.2%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 8	D. Boral Capital	Maintains	Buy → Buy	—	$0.76	$0.74	-2.0%	-5.1%	+1.2%	-4.1%	+1.5%	-0.1%
Mar 25	D. Boral Capital	Maintains	Buy → Buy	—	$0.73	$0.71	-2.7%	+5.5%	+0.0%	-5.1%	+0.0%	+3.3%
Mar 17	D. Boral Capital	Maintains	Buy → Buy	—	$0.81	$0.83	+2.4%	+0.9%	-5.4%	+1.8%	-4.5%	-1.6%
Mar 9	D. Boral Capital	Maintains	Buy → Buy	—	$0.87	$0.85	-2.0%	-3.0%	+3.3%	+0.9%	-3.0%	+1.1%
Dec 22	D. Boral Capital	Maintains	Buy → Buy	—	$0.81	$0.88	+8.5%	+3.8%	-0.1%	-2.7%	-2.1%	-5.0%
Nov 24	D. Boral Capital	Maintains	Buy → Buy	—	$1.10	$1.12	+1.8%	-3.6%	-1.9%	+12.5%	+1.7%	-1.7%
Aug 15	D. Boral Capital	Maintains	Buy → Buy	—	$1.17	$1.15	-1.7%	+1.7%	+5.0%	-7.2%	+1.7%	-3.4%
Jul 10	D. Boral Capital	Maintains	Buy → Buy	—	$2.09	$2.17	+3.8%	+1.0%	-1.9%	-3.4%	-1.0%	+2.5%
Dec 16	Maxim Group	Downgrade	Buy → Hold	—	$0.86	$0.86	+0.0%	+2.8%	+23.3%	+4.6%	+12.3%	+6.2%

Data updated apr 26, 2026 3:46pm · Source: massive.com